By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Boehringer Ingelheim Corporation 

P.O. Box 368
900 Ridgebury Road
Ridgefield  Connecticut  06877-0368  U.S.A.
Phone: 203-798-99-88 Fax: 203-791-62-34


Company News
Boehringer Ingelheim Corporation's Afatinib Meets Primary Endpoint In Phase 3 Study Of Head And Neck Cancer 9/29/2014 7:15:13 AM
Boehringer Ingelheim Corporation Release: Nintedanib* Receives Positive CHMP Opinion For Second-Line Treatment Of Patients With Adenocarcinoma Of The Lung 9/26/2014 8:17:23 AM
Boehringer Ingelheim Corporation Plans To Cut Up To 600 Jobs 9/23/2014 6:42:19 AM
Boehringer Ingelheim Corporation Will Pay Up To $600 Million For CureVac GmbH Lung Cancer Vaccine 9/18/2014 6:21:48 AM
Boehringer Ingelheim Corporation Release: Type 2 Diabetes: Investigational Empagliflozin/Linagliptin Combination Tablet Shows Sustained Reduction In Blood Glucose In Phase 3 Study 9/16/2014 9:22:37 AM
To Mark Pulmonary Fibrosis Awareness Month, Boehringer Ingelheim Corporation Announces Discovery Channel Documentary On Idiopathic Pulmonary Fibrosis 9/10/2014 9:47:18 AM
Diabetes: Boehringer Ingelheim Corporation And Eli Lilly and Company (LLY) Announce Data On Portfolio To Be Presented At The 50th EASD Annual Meeting 9/9/2014 12:16:56 PM
Boehringer Ingelheim Corporation Release: TONADO™ - Further Lung Function And Quality Of Life Benefits With Tiotropium + Olodaterol Respimat® FDC* In COPD 9/8/2014 10:55:08 AM
BeiGene Co.,Ltd Signs China CMO Deal With Boehringer Ingelheim Corporation 9/4/2014 2:41:40 PM
Boehringer Ingelheim Corporation Release: European Society of Cardiology Congress 2014 Hot Line Session: Favourable Effect Of Pradaxa® On Kidney Function Over Time Compared To Warfarin 9/2/2014 11:07:44 AM